Yeqing Gu1,2, Ge Meng2,3, Qing Zhang4, Li Liu4, Hongmei Wu2, Shunming Zhang2, Yawen Wang2, Tingjing Zhang2, Xuena Wang2, Xingqi Cao2, Huiping Li2, Yunyun Liu2, Xiaoyue Li2, Xiaohe Wang2, Shaomei Sun4, Ming Zhou4, Qiyu Jia4, Kun Song4, Kaijun Niu5,6,7,8. 1. Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China. 2. Nutritional Epidemiology Institute and School of Public Health, Tianjin Medical University, Tianjin, China. 3. Department of Toxicology and Sanitary Chemistry, School of Public Health, Tianjin Medical University, Tianjin, China. 4. Health Management Centre, Tianjin Medical University General Hospital, Tianjin, China. 5. Nutritional Epidemiology Institute and School of Public Health, Tianjin Medical University, Tianjin, China. nkj0809@gmail.com. 6. Health Management Centre, Tianjin Medical University General Hospital, Tianjin, China. nkj0809@gmail.com. 7. Tianjin Key Laboratory of Environment, Nutrition and Public Health, Tianjin, China. nkj0809@gmail.com. 8. Center for International Collaborative Research on Environment, Nutrition and Public Health, Tianjin, China. nkj0809@gmail.com.
Abstract
PURPOSE: Thyroid hormones (THs) have multiple effects on lipid synthesis, mobilization, and degradation, suggesting that THs may affect the development of dyslipidemia. However, prospective studies on the association between serum THs levels and incident dyslipidemia in euthyroid subjects are limited. Therefore, we conducted a cohort study (~5-year follow-up period, median: 3.0 years) to explore whether THs can affect incident dyslipidemia in a general euthyroid population aged 18 years old and over. METHODS: Dyslipidemia is characterized by elevated total cholesterol (TC), triglyceride (TG), or low-density lipoprotein cholesterol (LDL-C), or reduced high-density lipoprotein cholesterol (HDL-C). Serum free triiodothyronine (FT3), free thyroxine (FT4), and thyroid-stimulating hormone (TSH) were determined by chemiluminescence immunoassay. Multivariable Cox proportional hazards regression models were used to assess the association between baseline FT3, FT4, TSH, and the risk of various dyslipidemias. RESULTS: During follow-up period, the incidence of elevated TC, TG, LDL-C, and reduced HDL-C was 29.3%, 20.7%, 24.8%, and 19.5%, respectively. After adjustment for multiple confounders, we found that per unit increase in FT3 concentrations were associated with decreased incidence of elevated TC and LDL-C, and the hazard ratios (95% confidence interval) were 0.87 (0.79-0.97) (P < 0.01) and 0.897 (0.808-0.995) (P = 0.04), respectively. We also found a weak positive association between TSH and incidence of reduced HDL-C (P = 0.02). However, we found no association between FT4 and incident dyslipidemia. CONCLUSIONS: Our results demonstrated that low FT3 was associated with high dyslipidemia risk, especially for elevated TC and LDL-C, and that TSH had a weak positive effect on incidence of reduced HDL-C.
PURPOSE: Thyroid hormones (THs) have multiple effects on lipid synthesis, mobilization, and degradation, suggesting that THs may affect the development of dyslipidemia. However, prospective studies on the association between serum THs levels and incident dyslipidemia in euthyroid subjects are limited. Therefore, we conducted a cohort study (~5-year follow-up period, median: 3.0 years) to explore whether THs can affect incident dyslipidemia in a general euthyroid population aged 18 years old and over. METHODS:Dyslipidemia is characterized by elevated total cholesterol (TC), triglyceride (TG), or low-density lipoprotein cholesterol (LDL-C), or reduced high-density lipoprotein cholesterol (HDL-C). Serum free triiodothyronine (FT3), free thyroxine (FT4), and thyroid-stimulating hormone (TSH) were determined by chemiluminescence immunoassay. Multivariable Cox proportional hazards regression models were used to assess the association between baseline FT3, FT4, TSH, and the risk of various dyslipidemias. RESULTS: During follow-up period, the incidence of elevated TC, TG, LDL-C, and reduced HDL-C was 29.3%, 20.7%, 24.8%, and 19.5%, respectively. After adjustment for multiple confounders, we found that per unit increase in FT3 concentrations were associated with decreased incidence of elevated TC and LDL-C, and the hazard ratios (95% confidence interval) were 0.87 (0.79-0.97) (P < 0.01) and 0.897 (0.808-0.995) (P = 0.04), respectively. We also found a weak positive association between TSH and incidence of reduced HDL-C (P = 0.02). However, we found no association between FT4 and incident dyslipidemia. CONCLUSIONS: Our results demonstrated that low FT3 was associated with high dyslipidemia risk, especially for elevated TC and LDL-C, and that TSH had a weak positive effect on incidence of reduced HDL-C.
Authors: Zeljko Reiner; Alberico L Catapano; Guy De Backer; Ian Graham; Marja-Riitta Taskinen; Olov Wiklund; Stefan Agewall; Eduardo Alegria; M John Chapman; Paul Durrington; Serap Erdine; Julian Halcox; Richard Hobbs; John Kjekshus; Pasquale Perrone Filardi; Gabriele Riccardi; Robert F Storey; David Wood Journal: Eur Heart J Date: 2011-06-28 Impact factor: 29.983
Authors: Annemieke Roos; Stephan J L Bakker; Thera P Links; Rijk O B Gans; Bruce H R Wolffenbuttel Journal: J Clin Endocrinol Metab Date: 2006-11-07 Impact factor: 5.958
Authors: Bruce H R Wolffenbuttel; Hanneke J C M Wouters; Sandra N Slagter; Robert P van Waateringe; Anneke C Muller Kobold; Jana V van Vliet-Ostaptchouk; Thera P Links; Melanie M van der Klauw Journal: BMC Endocr Disord Date: 2017-10-16 Impact factor: 2.763